The first patients received doses of an oral thin-film formulation of montelukast in a clinical trial testing the treatment’s potential for Parkinson’s disease. The placebo-controlled MONTPARK trial will test how well a high dose of Montelukast VersaFilm, a proprietary formulation being developed by IntelGenx, can slow the progression…
IntelGenx has won approval from the Swedish Medical Products Agency (MPA) to conduct a Phase 2 trial on Montelukast Versafilm, its proprietary oral thin film formulation, in people with Parkinson’s disease. The Phase 2 MONTPARK multicenter study will investigate the effectiveness of oral high-dose Montelukast on the progression…
IntelGenx has finalized a research grant agreement with Karolinska University Hospital, Sweden for a placebo-controlled clinical study of Montelukast VersaFilm, an experimental oral thin film formulation for Parkinson’s disease. Manufacturing of both the treatment and its placebo are underway ahead of the study, which will be led by…
IntelGenx has teamed up with a renowned neurologist at the Karolinska Institute, Sweden to conduct a clinical trial on Montelukast VersaFilm, its proprietary oral thin film formulation, in people with Parkinson’s disease. The multicenter trial, expected to start between July and September, will be led by Per Svenningsson,…
Get regular updates to your inbox.
